Comparative evaluation of CLIA and EIA for Quantiferon-TB Gold Plus.
CLIA
EIA
IGRA
LTBI
Journal
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
ISSN: 1600-0463
Titre abrégé: APMIS
Pays: Denmark
ID NLM: 8803400
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
30
10
2019
accepted:
03
01
2020
pubmed:
25
1
2020
medline:
27
5
2020
entrez:
25
1
2020
Statut:
ppublish
Résumé
The purpose of this study was to compare the Quantiferon-TB Gold Plus test analysed with chemiluminescence immunoassay (CLIA) to immunoassay (EIA). One hundred and twenty-five clinical specimens submitted to Karolinska University Hospital for Quantiferon-TB Gold Plus analysis were used to analyse agreement of the CLIA and EIA assays. The imprecision on CLIA was determined by analysis of pooled clinical samples of antigen tubes (TB1 and TB2), a reference material from National Institute for Biological Standards and Control (NIBSC 82/587) and two controls of the test. Recovery on CLIA was determined by analysis of the TB1 and TB2 samples and NIBSC 82/587. Concordant results were obtained for 110 (88.0%) of 125 samples with cut-off including a borderline range. With no borderline range, 121 of 125 samples (96.8%) showed concordant results. Repeatability had a coefficient of variation (CV) of 14.9%. Reproducibility for pooled clinical samples TB1 and TB2 had a CV of 10.5% and 11.0%, respectively, and for the NIBSC 82/587 7.45%, and kit controls 31.0% respective 12.2%. Overall recovery had a mean of 94.1% (SD 12%). We concluded that Quantiferon-TB Gold Plus analysed with the CLIA assay shows good concordance with EIA and acceptable imprecision.
Substances chimiques
Antigens, Bacterial
0
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
343-349Informations de copyright
© 2020 APMIS. Published by John Wiley & Sons Ltd.
Références
Global Tuberculosis Report 2019. Geneva: World Health Organization (WHO); 2019.
Petersen E, Chakaya J, Jawad FM, Ippolito G, Zumla A. Latent tuberculosis infection: diagnostic tests and when to treat. Lancet Infect Dis 2019;19:231-3.
Petruccioli E, Vanini V, Chiacchio T, Cuzzi G, Cirillo DM, Palmieri F, et al. Analytical evaluation of QuantiFERON- Plus and QuantiFERON- Gold In-tube assays in subjects with or without tuberculosis. Tuberculosis (Edinburgh, Scotland) 2017;106:38-43.
Petruccioli E, Chiacchio T, Vanini V, Cuzzi G, Codecasa LR, Ferrarese M, et al. Effect of therapy on Quantiferon-Plus response in patients with active and latent tuberculosis infection. Sci Rep 2018;8:15626.
Public Health Agency of Sweden. Recommendations on preventive measures against tuberculosis, 3rd ed. Sweden: Stockholm, 2017.
Jonsson J, Westman A, Bruchfeld J, Sturegard E, Gaines H, Schon T. A borderline range for Quantiferon Gold In-Tube results. PLoS ONE 2017;12:e0187313.
Doménech J. Passing-Bablok & Bland-Altman methods: User-written command agree for Stata. 1.1.7s ed. Barcelona: Graunt 21.